Figure 1
From: Antithyroid drug-induced leukopenia and G-CSF administration: a long-term cohort study
Maximum dose of ATD in patients with leukopenia and G-CSF administration. (A) The proportions of patients with leukopenia at the maximum dose of MMI and PTU have been compared. (B) The proportion of patients receiving the maximum dose of MMI or PUT who were administered G-CSF have been compared. The proportions of patients with ATD-induced leukopenia were comparable between the MMI and PTU groups (1.4% and 1.8%, respectively. P = 0.17). Among patients treated with MMI, the incidence of leukopenia was significantly higher in those receiving high-dose MMI than in those receiving low-dose MMI (RR 2.9, 95%CI 2.1-4.0 P < 0.01). The proportions of patients with G-CSF administration were also comparable between the MMI and PTU groups (0.3%, 0.2%. P = 0.36). Among patients treated with MMI, the incidence of G-CSF administration was also significantly higher in patients receiving high-dose MMI than in those receiving low-dose MMI (RR 2.6, 95% CI 1.3–5.1, P < 0.01). *The Χ2 test was performed. **Risk ratios (RRs) have been calculated by dividing the high-dose MMI incidence by the low-dose MMI incidence for leukopenia and G-CSF administration. ATD antithyroid drug, G-CSF granulocyte colony-stimulating factor, MMI methimazole, PTU propylthiouracil.
